Pan-(K)RAS: the second half that came early as clinic entries accelerate

Race into the clinic accelerates

The Pan-(K)RAS race has shifted into what industry watchers call the “second half” sooner than expected. Kestrel announced its Pan-(K)RAS inhibitor KST-6051 has won IND clearance, and Chia Tai Tianqing (正大天晴) quickly followed with clinical approval for its Pan-(K)RAS candidate TQB3205. It has been reported that roughly 20 Pan-(K)RAS programs worldwide have already entered the clinic, and that number continues to climb as companies rush to cover KRAS mutations beyond the approved G12C agents. Why the scramble? Current approved KRAS drugs target a narrow patient group and face resistance, while early biotech successes and blockbuster M&A rumors have turbo‑charged investor and R&D appetite.

Leaders, challengers and competing strategies

Revolution Medicines is the field’s early front‑runner: its Daraxonrasib (RMC‑6236) has shown eye‑catching early data and earned FDA breakthrough therapy recognition for treated pancreatic ductal adenocarcinoma (PDAC) patients; it has been reported that Merck (MSD) reportedly explored an acquisition of Revolution for roughly $30 billion earlier this year, a sign of perceived strategic value even if talks fell apart. Tight on its heels is 加科思 (Jiakesi) with JAB‑23E73 — a KRAS‑selective small molecule that, in early safety data, delivered lower high‑grade TRAE rates and fewer skin toxicities than RMC‑6236 in small cohorts, suggesting selectivity may be a clinical differentiator. But these are early, non‑head‑to‑head signals; larger trials will decide the winners.

Multiple scientific routes — who will be best‑in‑class?

Companies are pursuing a spread of tactics: molecular glues (e.g., Jinfang Pharma (劲方医药)’s GFH276 and Jiayue Pharma (嘉越医药)’s JYP0015 licensed to Erasca), SOS1‑targeting approaches such as TQB3205 from Chia Tai Tianqing, combination regimens (BeiGene (百济神州)’s BGB‑53038 trials with PD‑1 and EGFR agents), and even targeted protein degradation (Astellas’ ASP5834). KST‑6051 and TQB3205 both claim activity against KRAS in both GTP‑ and GDP‑bound states — an “on/off” coverage that has become a new standard. Geopolitics and regulatory paths matter too: cross‑border collaborations, U.S. and Chinese IND/approval routes, and export controls can shape who gets to late‑stage data first. Who will emerge best‑in‑class? The answer will come only from larger, randomized trials — but the field has already entered its most unforgiving phase.